Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy

This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.

Trial Details

NCT ID

NCT02657785

Phase

PHASE2 / PHASE3

Sponsor

Navy General Hospital, Beijing

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

R-IDARAM plus intrathecal chemotherapy

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →